September 1, 2015
A nine-gene molecular prognostic index provided accurate risk stratification and may be used to inform adjuvant therapy for patients with early-stage non–small cell lung cancer, according to the results of a retrospective analysis.
“We set out to develop a predictor that could identify which patients with early-stage NSCLC are at highest risk for dying of the disease,” Maximilian Diehn, MD, PhD, assistant professor of radiation oncology at Stanford University School of Medicine, told HemOnc Today. “Such a predictor could potentially help identify patients who would be most likely to benefit from adjuvant therapy after definitive local treatment. We also wanted our predictor to incorporate both gene expression and clinical risk factors in order to take advantage of both types of information.”